Viatris, Inc. (VTRS)
|Net Income (ttm)||266.40M|
|Trading Day||January 22|
|Day's Range||17.10 - 17.52|
|52-Week Range||16.19 - 18.74|
High dividend yields plus low valuations could be just the ticket for income-seeking investors.
I received shares in Viatris following the spin-off from Pfizer. The company will only start paying a dividend next year.
It's no bull: These stocks are set to weather a potential storm.
Growing your dividend income takes time and consistency. In December, we (my wife and I) received a total of $5,483.32 of dividend income.
All three also offer attractive dividends.
Whether or not you believe that Viatris can make you rich depends on how strongly you believe in biosimilars.
Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason -- they believe the stock price will rise and they want to profit from it. So insider b...
PITTSBURGH, Dec. 18, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced that the U.S. District Court for the District of Kansas entered summary judgment in Mylan's favor in the l...
Viatris Inc. Recommends Caution on TRC Capital Corp.'s Attempt to Acquire Shares at a Significant Discount via Mini-Tender Offer
PITTSBURGH, Dec. 15, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) has been notified of an unsolicited "mini-tender" offer by TRC Capital Corporation ("TRC") to purchase up to 6,000,000 sha...
Viatris (VTRS) announces job cuts as part of additional details of its previously disclosed multi-year global restructuring initiative.
Shares of Viatris Inc. were down 0.2% in premarket trading on Friday after the company said it plans to close or divest up to 15 manufacturing sites and may cut up to 9,000 jobs, or 20% of its...
PITTSBURGH, Dec. 11, 2020 /PRNewswire/ -- Viatris Inc. (NASDAQ: VTRS) today announced additional details of its previously disclosed multi-year global restructuring initiative. The restructuri...
Viatris, a healthcare company, manufactures and distributes various medicines for patients in the United States and internationally. Its portfolio comprises approximately 1,400 approved molecules across a range of therapeutic areas, including non-communicable and infectious diseases; complex generic and branded medicines; a portfolio of biosimilars; and various over-the-counter consumer products, as well as active pharmaceutical ingredients. The company is headquartered in Canonsburg, Pennsylvania.
Drug Manufacturers-Specialty & Generic
|Stock Exchange |
|Ticker Symbol |
In 2019, Viatris's revenue was $11.50 billion, an increase of 0.58% compared to the previous year's $11.43 billion. Earnings were $16.80 million, a decrease of -95.23%.
The average 12-month stock price forecast for Viatris is 21.88, which is an increase of 25.53% from the latest price.